Does rivaroxaban prevent stroke or systemic embolism in patients with nonvalvular atrial fibrillation compared to warfarin and other DOACs?
This review indicates that rivaroxaban is superior to warfarin and comparable to other DOACs for stroke prevention in nonvalvular atrial fibrillation, though it may carry a higher bleeding risk than other DOACs.
Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, a common arrhythmia. In this review, we summarize the effectiveness of rivaroxaban versus warfarin and the DOACs dabigatran, apixaban and edoxaban. The primary focus is on primary evidence from clinical trials, indirect comparison studies and real-world studies. While there are gaps in the literature, the evidence thus far indicates that rivaroxaban is superior to warfarin and similar to dabigatran, apixaban and edoxaban for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, although rivaroxaban may be associated with an elevated bleeding risk compared with other DOACs.
Norby et al. (Mon,) studied this question.